Enliven Therapeutics (ELVN) Total Current Liabilities (2019 - 2026)

Enliven Therapeutics has reported Total Current Liabilities for 8 years, with the latest figure at $11.5 million in Q1 2026.

• Quarterly Total Current Liabilities fell 17.79% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 17.79% YoY) and the FY2025 annual result came in at $16.6 million, up 4.1% from the prior year.
• Total Current Liabilities slipped to $11.5 million in Q1 2026 per ELVN's latest filing, from $16.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $25.9 million in Q4 2023 and troughed at $1.8 million in Q3 2022.
• A 5-year average of $13.7 million and a median of $14.0 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities slumped 74.71% in 2022, then soared 564.41% in 2023.
• Over 5 years, Total Current Liabilities stood at $9.7 million in 2022, then surged by 166.54% to $25.9 million in 2023, then tumbled by 38.54% to $15.9 million in 2024, then grew by 4.1% to $16.6 million in 2025, then sank by 30.67% to $11.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $11.5 million, $16.6 million, and $14.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.